Abstract

Although the liver is a regenerating organ, excessive loss of liver volume (LV) can cause fatal liver failure. It is unclear whether LV is correlated with age; however, it is known that liver function decreases with age. In addition, the gender-related role of LV remains unclear. This study aimed to investigate the changes in LV by age and gender. Between January and December 2018, 374 consecutive patients who underwent abdominal multidetector computed tomography (MDCT) for any abdominal examinations were enrolled. LV was evaluated using MDCT. The relationship between the LV and body mass index (BMI), body surface area (BSA), age, and gender was investigated. The modified LV (mLV) was calculated by a formula measured LV × 1.5/BSA. LV correlated to BSA more than to BMI in both the males (R: 0.559 vs. 0.416) and females (R: 0.479 vs. 0.300) in our study. Age was negatively correlated to LV and BSA, and correlated to LV more than to BSA in males (R: 0.546 vs. 0.393) and females (R: 0.506 vs. 0.385). In addition, the absolute slope between age and LV in the males was higher than that in the females (14.1 vs. 10.2, respectively). Furthermore, the absolute slope of age and mLV in the males was slightly higher than in the females (9.1 vs. 7.3, respectively). In conclusion, LV in the normal liver is correlated to age rather than the one in the diseased liver. Liver volume in the males decreased more with age than LV in the females.

Introduction

The liver can regenerate to recover the original mass once it is removed surgically [1, 2]. In clinical settings, liver resection is required to remove liver tumors or to donate for living organ transplantation [3, 4]. Excess loss of liver volume (LV) due to oversized hepatectomy can lead to fatal liver failure because the liver regenerates insufficiently [5–7]. Due to the fact that the
liver cannot regenerate in some instances, considerable research has been conducted in an effort to overcome the limitation of liver regeneration.

Studies have investigated liver regeneration mechanisms in both in vivo and in vitro models [8, 9]. However, some hepatocytes could regenerate as stem cells; 90% volume loss causes liver failure [7]. In living liver transplantation, up to 70% of the liver can be removed from the donor organ, and a minimum of 30% LV should be preserved for donor safety [10, 11]. Posthepatectomy liver failure (PHLF) incidence is reportedly 8% to 12% [12–15]. The regenerative ability differs by gender and aging. Bachellier et al. reported that PHLF in male patients was higher than that in female patients [16]. It has also been reported that hepatectomy in elderly patients >70 years old has a high incidence of mortality [17]. However, the exact difference between the genders along with aging, is not well understood.

LV is affected by various factors such as body physique, blood flow, hormones, and liver damage. LV in chronic hepatitis and liver cirrhosis is lower than that in the normal liver [18]. Irreversible liver failure also occurs in fulminant hepatitis, which causes rapid liver atrophy. Specifically, the progression of liver disease affects LV. Conversely, body physique affects LV. The body’s physique increases with age due to decreased basic metabolism by the end of middle age of approximately 60 years. However, physique decreases afterward, resulting in frailty in the elderly. In addition, body physique between the genders differs from hormonal and metabolic characteristics. However, the relationships between aging and LV are not well known, and the underlying mechanisms of how body physic and metabolism affect LV is also unclear.

Traditionally, personal LV was estimated from body height and weight [19–23]. Accurate liver volumetry measures are now possible using multidetector-raw computed tomography (MDCT). Although attempts have been made with ultrasound and MRI [24, 25], MDCT is significantly superior in spatial resolution and reproducibility. Clarifying the relationship between LV and liver function in hepatectomy is important to avoid PHLF. Various formulas for estimating standard LV have been reported [19, 22, 26–28]. However, few of them considered the effect of gender, and none of them addressed the effect of aging.

This study aimed to investigate the changes in LV by aging and gender differences. We used modified LV (mLV) adjusted by the constant body surface area to avoid physical bias. This study showed a clear difference between the genders along with the aging effect using the latest radiological technology.

**Materials and methods**

**Patient selection and scan parameters**

Between January 2018 and December 2018, 374 consecutive patients who underwent abdominal dynamic studies using MDCT were enrolled in this study. Patients with previous malignancies, past catheterization, or past hepatectomy were excluded from this series. There was no duplicated participant.

Clinical laboratory tests, including albumin (ALB), bilirubin (Bil), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet (PLT), were evaluated before computed tomography examination.

LV was evaluated by 80-law MDCT (Aquilion PRIME; Canon Medical Systems, Tokyo, Japan). The images were obtained by three-phase methods, including the late arterial phase, portal venous phase, and late phase. Nonionic contrast material (Iomeron; Eisai, Tokyo, Japan) was administered intravenously for 30 seconds utilizing a power injector (Dual Shot GX7; Nemoto Kyorindo, Tokyo, Japan). The scanning delays of the late arterial phase were individually determined using a bolus-tracking technique. A circular cursor was placed on the aorta, and the late arterial phase scan was started 15 seconds after a 200 Hounsfield unit.
threshold was reached. The portal venous phase was acquired 30 seconds after the late arterial phase scan, and the late phase was acquired 180 seconds after the start of administration of the contrast material. A ZIO STATION 2 (Ziosoft Inc., Tokyo, Japan) was used to calculate the LV. The images of the portal venous phase were used for volumetry.

Vascular vessels such as the portal vein, hepatic vein, and inferior vena cava were excluded from volumetry (Fig 1). Additionally, benign tumors, such as liver cysts and hemangiomas, were excluded from volumetric measurements.

The relationship between the measured LV and BMI, BSA, age, and gender was investigated. For BSA, the formula of DuBois (BSA [m$^2$] = 0.007184 × height [cm]$^{0.725}$ × weight [kg]$^{0.425}$) was used [29]. The mLV was calculated by a formula measuring LV×1.5/BSA, based on a BSA of 1.5 m$^2$ for all patients.

This study was conducted according to the ethical guidelines of the Declaration of Helsinki. The Internal Review Board of Sapporo Medical University approved this study (ID: 302–195, approval date: February 14, 2019). Written informed consent was obtained from all participants prior to registry.

**Statistical analysis**

Patient demographics and perioperative laboratory tests were extracted from the database, and differences between the groups were compared using the chi-square test followed by a post-hoc 2 × 2 Fisher’s exact test. The unpaired t test was used for comparisons between the males and the females. The relationships among the various clinical parameters were evaluated using Spearman’s rank correlation coefficient. All calculations were performed using the JMP 15.0 software program (SAS Institute Inc., London, ON, CAN). All results were expressed as the mean, together with minimum and maximum levels. $P < 0.05$ was considered statistically significant.
Results and discussion

Table 1 shows the clinical background of the patients in this study. Characteristics including BMI, BSA, LV, mLV, AST, ALT, and PLT are significantly different between the males and the females. Conversely, the number of patients, age, ALB, and Bil were not significantly different between the groups. Table 2 shows the etiologies of the patients. In the males, 55 patients (28.6%) comprised the diseased liver group, and 137 patients (71.4%) comprised the normal liver group. In the females 44 patients (24.2%) comprised the diseased liver group, and 138 patients (75.8%) comprised the normal liver group. The etiologies between the groups were not significantly different.

![Figure 2a](https://doi.org/10.1371/journal.pone.0261094.g002a) ![Figure 2b](https://doi.org/10.1371/journal.pone.0261094.g002b)

LV is significantly correlated with BSA and BMI in the males and the females. The correlation (R) between LV and BSA is stronger than between LV and BMI in males and females (0.559 vs. 0.416 and 0.479 vs. 0.300, respectively).

### Table 1. Comparison of characteristics between male and female study participants.

|          | Male                  | Female                | P value |
|----------|-----------------------|-----------------------|---------|
| n        | 192                   | 182                   | -       |
| Age (years) | 66.7 ± 12.3           | 66.7 ± 12.3           | 0.9981  |
| BMI      | 22.74 ± 3.64          | 21.71 ± 3.13          | 0.0012  |
| BSA (m²) | 1.69 ± 0.16           | 1.47 ± 0.13           | <0.0001 |
| LV (mL)  | 1230.3 ± 316.9        | 995.3 ± 247.3         | <0.0001 |
| mLV (mL) | 1085.1 ± 234.9        | 1010.2 ± 213.7        | 0.0043  |
| ALB (g/dL)| 3.77 ± 0.59           | 3.81 ± 0.53           | 0.8271  |
| Bil (mg/dL)| 1.02 ± 2.22          | 0.83 ± 1.20           | 0.2215  |
| AST (IU/L)| 44.9 ± 91.3          | 32.1 ± 46.1           | 0.0116  |
| ALT (IU/L)| 43.6 ± 85.3          | 32.7 ± 71.5           | 0.0096  |
| PLT (10⁴/μL)| 20.29 ± 9.01        | 22.47 ± 7.95          | 0.0026  |

BMI: body mass index, BSA: body surface area, LV: liver volume, mLV: modified liver volume. ALB: albumin, Bil: bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, PLT: platelet. Data represent the mean ± standard deviation.

### Table 2. Clinical backgrounds of patients with underlying disease separated by gender.

|          | DL                     | Normal                 | DL                     | Normal                 |
|----------|------------------------|------------------------|------------------------|------------------------|
| Males n  | 55                     | 137                    | Female n               | 44                     | 138                   |
| HB hepatitis | 11                    | Esophago-Gastric cancer | 8                      | HB hepatitis           | 12                    | Esophago-Gastric cancer | 4  |
| HC hepatitis | 6                     | Colorectal cancer      | 17                     | HC hepatitis           | 5                     | Colorectal cancer      | 9  |
| Other hepatitis | 14                    | Retroperitoneal tumor  | 4                      | Other hepatitis        | 13                    | Retroperitoneal tumor  | 8  |
| HCC      | 6                      | Renal cancer           | 9                      | HCC                    | 2                     | Renal cancer           | 9  |
| Bile duct disease | 18                   | Pancreatitis           | 11                     | Bile duct disease      | 12                    | Pancreatitis           | 9  |
|          | Pancreatic tumor       | 61                     |                        |                        | Pancreatic tumor       | 70                    |                        |    |
|          | Metastatic tumor       | 5                      |                        |                        | Metastatic tumor       | 3                     |                        |    |
|          | Gallbladder stone      | 3                      |                        |                        | Gallbladder stone      | 3                     |                        |    |
|          | Gallbladder cancer     | 5                      |                        |                        | Gallbladder cancer     | 3                     |                        |    |
|          | Other tumors           | 14                     |                        |                        | Other tumors           | 20                    |                        |    |

DL: diseased liver, HCC: hepatocellular carcinoma.

https://doi.org/10.1371/journal.pone.0261094.t002
The slope between LV and BSA in the males is higher than in the females (1103.7 vs. 919.6, respectively). Scatter plots of the linear regression analysis between LV and age for the males and the females are shown in Fig 3a and 3b. Scatter plots between BSA and age for males and for females are shown in Fig 3c and 3d. Age was negatively correlated with LV and BSA. The correlation (R) between LV and age is stronger than between BSA and age in the males and females (0.546 vs. 0.393, and 0.506 vs. 0.385, respectively). Furthermore, the correlation between LV and age in the males is higher than that in the females (14.1 vs. 10.2, respectively).

Scatter plots of the linear regression analysis between mLV and age for the males and the females are shown in Fig 4a and 4b. The correlation (R) of the males for LV and BSA was comparable with that of the females (0.473 vs. 0.423, respectively). However, the slope of the correlation between mLV and age in the males is slightly higher than that in the females (9.1 vs. 7.3, respectively).

Scatter plots of the linear regression analysis between mLV and age for the males and females in the diseased liver group are shown in Fig 5a and 5b. Scatter plots between mLV and age for the males and females in the normal liver group are shown in Fig 5c and 5d. The correlation (R) in the diseased liver group between mLV and age was weaker than that in the normal liver group for the males and females (0.346 vs. 0.532, and 0.354 vs. 0.449, respectively).

Fig 2. Linear regression analysis of LV and BMI by gender (a, b). Linear regression analysis of LV and BSA by gender (c, d). LV is more strongly correlated with BSA than BMI, with the correlation being stronger in males.

https://doi.org/10.1371/journal.pone.0261094.g002
Furthermore, the slope of the correlation between mLV and age for the normal liver group in the males is slightly higher than that in the females (10.0 vs. 7.8, respectively).

Characteristics including BMI, BSA, LV, mLV, AST, ALT, and PLT differed significantly between males and females. However, the number of patients, age, ALB, and Bil did not differ significantly between the groups. Table 2 shows the etiologies of the patients. Among males, the diseased liver group comprised 55 patients (28.6%) and normal liver group comprised 137 patients (71.4%). Among females, the diseased liver group comprised 44 patients (24.2%) and normal liver group comprised 138 patients (75.8%). The etiologies between the groups were not significantly different.

Table 3 shows the correlation between LV and biochemical blood test data in males with normal and diseased liver. Bilirubin correlated with LV in the male diseased liver group (P = 0.004). Table 4 shows the correlation between LV and biochemical blood test data in females with normal and diseased liver. Platelets correlated with LV regardless of liver state in females (P < 0.001, P = 0.039). Table 5 shows the relationship between LV and normal liver in patients with liver disease separated by gender. The LV of females with cirrhosis was significantly smaller than that of females with normal liver (P = 0.048).
We found a clear relationship between LV, gender, and age from 374 consecutive MDCT volumetry measures. LV in the males was significantly higher than in the females. Furthermore, LV was significantly correlated with BSA rather than with BMI and negatively correlated with age at the same time. Finally, we found that LV was correlated with age in the normal liver but not in the diseased liver.

We showed a large difference in LV between males and females. The LV in the males became smaller than the LV in the females, along with aging. It could be due to hormonal differences between the genders [30]. Estrogen was found to be a hepatotropic factor, which could facilitate liver regeneration [31]. The role of estrogen in the liver in aging was previously unclear. However, it could play an important role in maintaining LV in the female, along with aging. Liver disease induces feminization in male patients due to deterioration of the estrogen metabolism [32]. Therefore, LV in the diseased male liver was maintained in elderly patients due to the elevation of estrogen levels.

LV showed a good correlation with BSA rather than with BMI. Yoshizumi et al. have shown that BSA is more correlated than BMI using deceased liver donors [22]. Vauthey et al. also conclude that BMI did not have an independent effect on LV [33]. The exact reasons for the difference between BSA and BMI to LV were unclear. It could be a mathematical issue associated with the formula. However, BSA could be correlated with visceral volume, whereas visceral volume could not be associated with BMI, which stands for visceral fat deposition. Therefore, LV would be more associated with height than with weight. Questions for further consideration are which formula is suitable to calculate real BSA and how a novel method may be invented to estimate BSA.

LV is correlated with age in the normal adult liver, but not in the diseased liver. Height is likely unchanged throughout life, however, weight may change due to loss of basic metabolism [34] and advancing frailty [35]. Therefore, BSA would be unstable throughout life. Thus, we need to modify LV after adjusting constant BSA. We clearly showed that LV would decrease with aging. It is unclear if a decrease in LV may produce a decrease in liver function. As shown in Tables 3 and 4, albumin and bilirubin may correlate with LV in the case of diseased liver in males, whereas platelets correlate with LV independently of background in females, although...

![Fig 4. Linear regression of the relationship between mLV and age in participants separated by gender when the BSA of the target group is assumed to be 1.5 m². The correlation between mLV and age is similar for males and females; however, the slope is slightly greater for males.](https://doi.org/10.1371/journal.pone.0261094.g004)
bilirubin was not significantly associated. As shown in Table 5, the LV in cases of females with cirrhosis tended to decrease, but no change was observed in males. Thus, it is possible to predict liver atrophy due to hormones and other factors in females. The fact that platelets correlate with LV regardless of background in females and that atrophy occurs in patients with cirrhosis.

Table 3. Correlation between liver volume and biochemical blood test data in normal and diseased liver groups of males.

| Males    | Normal liver (n = 137) | Diseased liver (n = 55) |
|----------|------------------------|-------------------------|
|          | R         | P value   | R         | P value   |
| Albumin  | 0.055     | 0.528     | 0.265     | 0.051     |
| Bilirubin| 0.044     | 0.613     | 0.385     | 0.004     |
| AST      | 0.060     | 0.487     | 0.201     | 0.142     |
| ALT      | 0.030     | 0.731     | 0.064     | 0.644     |
| PLT      | 0.123     | 0.158     | 0.144     | 0.294     |

AST: aspartate transaminase, ALT: alanine transaminase, PLT: platelet.

https://doi.org/10.1371/journal.pone.0261094.t003
suggests a stronger correlation between LV and liver function in females. In contrast, it may be more difficult to evaluate potential condition in males due to the discrepancy between LV and liver function. Given the differences between males and females in terms of LV and liver function, evaluations should be separated by gender. The LV in the diseased liver would be atrophic and reduced in size and weight in the acute phase of illness, and LV would be maintained in the chronic phase. Therefore, surgeons should consider both the liver function associated with liver disease and the age-related loss of LV when clinically planning hepatectomy.

Several criteria, such as Barcelona criteria [36], Makuuchi criteria [4], Sapporo criteria [37], and Hongkong criteria [38], have been established for liver resection. Furthermore, Vauthey et al. reported a consensus statement on the evaluation of hepatocellular carcinoma [39]. The consensus statement recommended that portal vein embolization be considered if the residual LV is low [39]. The volume for portal vein embolization depends on liver function, such as at least 20% in the normal liver, at least 30% in the injured liver, and at least 40% in the compensatory fibrous or cirrhotic liver. The statement represents clear relation between LV and its function depending on disease progression. As shown in this study, the aging effect should be included in future criteria for liver resection.

There are several limitations of this study. First, we did not recruit a normal patient population. Therefore, we are not sure if the normal liver in this study would represent a normal population. Second, we did not follow the patients, and therefore, all the data are independent. We

Table 4. Correlation between liver volume and biochemical blood test data in normal and diseased liver groups of females.

| Females | Normal liver (n = 138) | Diseased liver (n = 44) |
|---------|-----------------------|------------------------|
|         | R        | P value   | R        | P value   |
| Albumin | 0.080   | 0.350     | 0.304   | 0.045     |
| Bilirubin | 0.178  | 0.037     | 0.092   | 0.551     |
| AST     | 0.083   | 0.332     | 0.279   | 0.066     |
| ALT     | 0.030   | 0.725     | 0.129   | 0.404     |
| PLT     | 0.389   | < 0.0001  | 0.312   | 0.039     |

AST: aspartate transaminase, ALT: alanine transaminase, PLT: platelet.

https://doi.org/10.1371/journal.pone.0261094.t004

Table 5. Relationship between liver volume and normal liver in patients with liver disease separated by gender.

| Males | n   | Liver volume | P      | Females | n   | Liver volume | P      |
|-------|-----|--------------|--------|---------|-----|--------------|--------|
|       |     |              |        | Normal liver | 138 | 969.45       | -      |
|       |     |              |        | [974.36–1344.91] | 138 | [848.25–1132.28] | -      |
| Chronic hepatitis | 26 | 1205.36 | 0.526 | Chronic hepatitis | 26 | 944.81 | 0.787 |
|       |     | [1064.70–1341.97] |        | [805.91–1139.23] |       |        |        |
| Liver cirrhosis | 4  | 1118.39 | 0.798 | Liver cirrhosis | 7 | 697.74 | 0.048 |
|       |     | [1048.44–1343.17] |        | [551.91–1198.54] |       |        |        |
| HCC   | 5   | 1177.26 | 0.335 | HCC | 1 | 906.3 | 0.680 |
|       |     | [1051.61–1713.97] |        |        |       |        |        |
| Bile duct disease | 20 | 1230.81 | 0.085 | Bile duct disease | 10 | 981.09 | 0.591 |
|       |     | [1085.31–1386.46] |        | [792.94–1105.39] |       |        |        |

HCC: hepatocellular carcinoma.

https://doi.org/10.1371/journal.pone.0261094.t005
cannot exclude the possibility that any alteration would be due to the generation effect. Third, the degree, type, and stage of disease in affected livers were unknown. To exclude all bias, a large prospective trial is warranted.

Conclusion

We investigated the changes in LV between the genders along with aging. In conclusion, LV in the normal liver showed a negative correlation with age, and LV in the males was more correlated to aging than LV in the females. This study indicates that the aging effect on LV should be considered in future protocols for liver resection.

Supporting information

S1 File. (XLSX)

Acknowledgments

We thank Sandy Tan and Thomas Hui for their help in preparing this manuscript and their valuable discussions.

Author Contributions

Conceptualization: Kohei Harada, Toru Mizuguchi.

Data curation: Kohei Harada.

Formal analysis: Kohei Harada.

Investigation: Yoshiya Ohashi, Takeo Tanaka, Ayaka Chiba, Kanako Numasawa, Tatsuya Imai, Shun Hayasaka, Takahito Tsugiki.

Methodology: Kohei Harada, Toru Mizuguchi.

Supervision: Tomohiro Ishinuki, Koji Miyanishi, Minoru Nagayama.

Validation: Toru Mizuguchi.

Writing – original draft: Kohei Harada.

Writing – review & editing: Ichiro Takemasa, Junji Kato, Toru Mizuguchi.

References

1. Inoue Y, Fujii K, Ishii M, Kagota S, Tomioka A, Hamamoto H, et al. Volumetric and functional regeneration of remnant liver after hepatectomy. J Gastrointest Surg. 2019; 23(5):914–21. https://doi.org/10.1007/s11605-018-3985-5 PMID: 30264387.

2. Yasuda S, Nom T, Hokuto D, Yoshikawa T, Matsuo Y, Sho M. Liver Regeneration after major liver resection for hepatocellular carcinoma in the elderly. J Invest Surg. 2020; 33(4):332–8. https://doi.org/10.1080/08941939.2018.1517839 PMID: 30386925.

3. Gavrilidis P, Tobias A, Sutcliffe RP, Roberts KJ. Survival following right lobe split graft, living- and deceased-donor liver transplantation in adult patients: a systematic review and network meta-analysis. Transpl Int. 2018; 31(10):1071–82. https://doi.org/10.1111/tri.13317 PMID: 30016550.

4. Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003; 138(11):1198–206; discussion 206. Epub 2003/11/12. https://doi.org/10.1001/archsurg.138.11.1198 PMID: 14609667.

5. van den Broek MA, Olde Damink SW, Dejong CH, Lang H, Malago M, Jalan R, et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver 2008; 28(6):767–80. https://doi.org/10.1111/j.1478-3231.2008.01777.x PMID: 18647141.
6. Kauffmann R, Fong Y. Post-hepatectomy liver failure. Hepatobiliary surgery and nutrition. 2014; 3 (5):238–46. https://doi.org/10.3978/j.issn.2304-3881.2014.09.01 PMID: 25392835.

7. Shoup M, Gonen M, D’Angelica M, Jarnagin WR, Schwartz LH, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg, 2003; 7 (3):325–30. https://doi.org/10.1016/s1091-255x(02)00370-0 PMID: 12654556.

8. Tan CY, Lai RC, Wong W, Dan YY, Lim SK, Ho HK. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem cell research & therapy. 2014; 5(3):76. https://doi.org/10.1186/s13287-014-0067-5 PMID: 24915963.

9. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology. 2006; 43(2 Suppl 1):S45–53. https://doi.org/10.1002/hep.20969 PMID: 16447274.

10. Surman OS, Hertl M. Liver donation: donor safety comes first. Lancet. 2003; 362(9385):674–5. https://doi.org/10.1016/S0140-6736(03)12439-0 PMID: 12957084.

11. Sugawara Y, Makuchi M, Takayama T, Imamura H, Kaneko J, Ohkubo T. Safe donor heptectomy for living related liver transplantation. Liver Transpl, 2002; 8(1):58–62. https://doi.org/10.1053/jlts.2002.29761 PMID: 11799487.

12. Benzioni E, Lorenzin D, Baccarani U, Adani GL, Favero A, Cojutti A, et al. Resective surgery for liver tumor: a multivariate analysis of causes and risk factors linked to postoperative complications. Hepatobiliary & pancreatic diseases international: HBPD INT. 2006; 5(4):526–33. PMID: 17085337.

13. Ribeiro HS, Costa WL Jr., Diniz AL, Godoy AL, Herman P, Coudry RA, et al. Extended preoperative chemotherapy, extent of liver resection and blood transfusion are predictive factors of liver failure following resection of colorectal liver metastasis. Eur J Surg Oncol, 2011; 39(3):380–5. https://doi.org/10.1016/j.ejso.2011.09.001 PMID: 21351680.

14. Soreide JA, Deshpande R. Post heptectomy liver failure (PHLF)—Recent advances in prevention and clinical management. Eur J Surg Oncol, 2020. https://doi.org/10.1016/j.ejso.2020.09.001 PMID: 32943278.

15. Chin KM, Koh YX, Syn N, Teo JY, Goh BKP, Chew PC, et al. Early prediction of post-hepatectomy liver failure in patients undergoing major heptectomy using a phf prognostic nomogram. World J Surg, 2020; 44(12):4197–206. https://doi.org/10.1007/s00268-020-05713-w PMID: 32860142.

16. Bachellier P, Rosso E, Pessaux P, Oussoultzoglou E, Nobili C, Panaro F, et al. Risk factors for liver failure and mortality after heptectomy associated with portal vein resection. Ann Surg, 2011; 253(1):173–9. https://doi.org/10.1097/SLA.0b013e3181f193ba PMID: 21233614.

17. Saadat LV, Brajcich BC, Liu Y, Ko C, D’Angelica M. Defining the risk of liver failure after minor heptectomy: a NSQIP analysis of 7029 patients. HPB: the official journal of the International Hepato Pancreatic Biliary Association, 2020. https://doi.org/10.1016/j.hpb.2020.08.013 PMID: 32952033.

18. Son JH, Lee SS, Lee Y, Kang BK, Sung YS, Jo S, et al. Assessment of liver fibrosis severity using computed tomography-based liver and spleen volumetric indices in patients with chronic liver disease. Eur Radiol, 2020; 30(6):3486–96. https://doi.org/10.1007/s00330-020-06665-4 PMID: 32055946.

19. Fu-Gui L, Lu-Nan Y, Bo L, Yong Z, Tian-Fu W, Ming-Qing X, et al. Estimation of standard liver volume in Chinese adult living donors. Transplant Proc. 2009; 41(10):4052–6. https://doi.org/10.1016/j.transproceed.2009.08.079 PMID: 20005340.

20. Hashimoto T, Sugawara Y, Tamura S, Hasegawa K, Kishi Y, Kokudo N, et al. Estimation of standard liver volume in Japanese living liver donors. J Gastroenterol Hepatol, 2006; 21(11):1710–3. https://doi.org/10.1111/j.1440-1746.2006.04433.x PMID: 16884594.

21. Urata K, Kawasaki S, Matsunami H, Hashikura Y, Ikegami T, Ishizone S, et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 1995; 21(5):1317–21. PMID: 7737637.

22. Yoshizumi T, Gondolesi GE, Bodian CA, Jeon H, Schwartz ME, Fishbein TM, et al. A simple new formula to assess liver weight. Transplant Proc. 2003; 35(4):1415–20. https://doi.org/10.1016/s0041-1345(03)00482-2 PMID: 12826175.

23. Yu HC, You H, Lee H, Jin ZW, Moon JL, Cho BH, Estimation of standard liver volume for liver transplantation in the Korean population. Liver Transpl, 2004; 10(6):779–83. https://doi.org/10.1002/lt.20188 PMID: 15162473.

24. Morino Y, Enkhbold C, Imura S, Ikemoto T, Iwahashi S, Saito YU, et al. Accurate estimation of functional liver volume using gd-eob-dtpa mri compared to mdct/(99m)t-c-spect fusion imaging. Anticancer Res, 2017; 37(10):5693–700. https://doi.org/10.21873/anticancer.12006 PMID: 28982888.

25. Surasi DSS, Jazbeh S, Nicek ZS, Zanabria RG, Wells RT, Patel A, et al. Utility of longitudinal measurement of the liver with ultrasound in comparison to computed tomography liver volume in assessing hepatomegaly. Ultrasound quarterly. 2019. https://doi.org/10.1097/RUQ.0000000000000472 PMID: 31517741.
26. Chan SC, Liu CL, Lo CM, Lam BK, Lee EW, Wong Y, et al. Estimating liver weight of adults by body weight and gender. World J Gastroenterol. 2006; 12(14):2217–22. https://doi.org/10.3748/wjg.v12.i4.2217 PMID: 16610024.

27. Chouker A, Martignoni A, Dugas M, Eisenmenger W, Schauer R, Kaufmann I, et al. Estimation of liver size for liver transplantation: the impact of age and gender. Liver Transpl. 2004; 10(5):678–85. https://doi.org/10.1002/lt.20113 PMID: 15108261.

28. Yuan D, Lu T, Wei YG, Li B, Yan LN, Zeng Y, et al. Estimation of standard liver volume for liver transplantation in the Chinese population. Transplant Proc. 2008; 40(10):3536–40. https://doi.org/10.1016/j.transproceed.2008.07.135 PMID: 19100432.

29. Du Bois D, Du Bois E. A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med. 1916; 17:863–71.

30. Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol. 2006; 20(11):2613–29. https://doi.org/10.1210/me.2006-0007 PMID: 16543404.

31. Biondo-Simoes MLP, Erdmann TR, Ioshii SO, Matias JE, Calixto HL, Schebelski DJ. The influence of estrogen on liver regeneration: an experimental study in rats. Acta cirurgica brasileira. 2009; 24(1):3–6. https://doi.org/10.1590/s0102-86502009000100002 PMID: 19169534.

32. Maruyama Y, Adachi Y, Aoki N, Suzuki Y, Shinohara H, Yamamoto T. Mechanism of feminization in male patients with non-alcoholic liver cirrhosis: role of sex hormone-binding globulin. Gastroenterol Jpn. 1991; 26(4):435–9. https://doi.org/10.1007/BF02782811 PMID: 19161511.

33. Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Fenstermacher MJ, Loyer EM, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002; 8(3):233–40. https://doi.org/10.1053/jlts.2002.31654 PMID: 11910568.

34. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, et al. Origins of life-time health around the time of conception: causes and consequences. Lancet. 2018; 391(10132):1842–52. https://doi.org/10.1016/S0140-6736(18)30312-X PMID: 29673874.

35. Buchard B, Boirie Y, Cassagnes L, Lamblin G, Coilly A, Abergel A. Assessment of malnutrition, sarcopenia and frailty in patients with cirrhosis: which tools should we use in clinical practice? nutrients. 2020; 12(1). https://doi.org/10.3390/nu12010186 PMID: 31936597.

36. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 10(2 Suppl 1):S115–20. Epub 2004/02/06. https://doi.org/10.1002/lt.20034 PMID: 14762851.

37. Harada K, Nagayama Y, Ohashi Y, Chiba A, Numasawa K, Meguro M, et al. Scoring criteria for determining the safety of liver resection for malignant liver tumors. World J Meta-Anal. 2019; 7(5):234–48. https://doi.org/10.13105/wjma.v7.i5.234

38. Poon RT, Fan ST. Assessment of hepatic reserve for indication of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg. 2005; 12(1):31–7. Epub 2005/03/09. https://doi.org/10.1007/s00534-004-0945-0 PMID: 15754097.

39. Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB: the official journal of the International Hepato Pancreat Biliary Association. 2010; 12(5):289–99. Epub 2010/07/02. https://doi.org/10.1111/j.1477-2574.2010.00181.x PMID: 20590901.